Monoclonal Antibody Collaboration and Licensing Deals 2019-2026
Monoclonal Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2026
Request your free report sample
The definitive benchmark for monoclonal antibody dealmaking
Monoclonal antibody partnering is driven by a well-established yet continuously evolving class of biologic therapies, with deal structures reflecting both mature development pathways and ongoing innovation in next-generation antibody formats.
This report provides a comprehensive and structured analysis of 740+ monoclonal antibody collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.
Establish a clear view of market standards
The report enables a precise understanding of how monoclonal antibody deals are structured in practice, allowing you to:
-
Benchmark comparable transactions with confidence
Detailed analysis of upfronts, milestones, and royalty structures across relevant deals -
Define realistic market parameters
Clear insight into how deal terms vary by development stage, antibody type, and partner profile -
Support valuation and structuring decisions with evidence
Ground internal discussions in real transaction data rather than assumptions -
Understand how leading companies approach dealmaking
Visibility into partner behaviour and recurring deal structures across a competitive and innovation-driven biologics landscape
Full visibility into deal structure and execution
Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.
This includes:
-
Rights granted and retained
-
Development and commercialization responsibilities
-
Financial structures and payment triggers
-
Key contractual provisions and protections
This level of transparency is critical to understanding how value, risk, and control are allocated within monoclonal antibody partnerships, particularly in areas involving differentiated biologics and evolving therapeutic strategies.
Designed for real-world BD and strategy use
The report is widely used to:
-
Structure and benchmark biologics transactions
-
Prepare for negotiations with well-defined market context
-
Evaluate licensing and co-development opportunities
-
Support internal strategy with robust, defensible data
What’s included
-
740+ monoclonal antibody collaboration and licensing deals
-
Financial terms, including upfronts, milestones, and royalties where disclosed
-
Fully searchable deal directory (by company, therapy, and antibody type)
-
Direct access to SEC-filed agreements and source documents
-
Analysis of deal trends, key transactions, and active dealmakers
A trusted, evidence-based reference for monoclonal antibody dealmaking
Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how monoclonal antibody partnerships are structured, negotiated, and valued.
Monoclonal Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:
• Understand deal trends since 2019
• Browse monoclonal antibody collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in monoclonal antibody dealmaking
2.1. Introduction
2.2. Monoclonal antibody deals over the years
2.3. Most active monoclonal antibody dealmakers
2.4. Monoclonal antibody deals by deal type
2.5. Monoclonal antibody deals by therapy area
2.6. Monoclonal antibody deals by industry sector
2.7. Deal terms for monoclonal antibody deals
2.7.1 Monoclonal antibody deals headline values
2.7.2 Monoclonal antibody deal upfront payments
2.7.3 Monoclonal antibody deal milestone payments
2.7.4 Monoclonal antibody royalty rates
Chapter 3 – Leading monoclonal antibody deals
3.1. Introduction
3.2. Top monoclonal antibody deals by value
Chapter 4 – Most active monoclonal antibody dealmakers
4.1. Introduction
4.2. Most active monoclonal antibody dealmakers
4.3. Most active monoclonal antibody deals company profiles
Chapter 5 – Monoclonal antibody contracts dealmaking directory
5.1. Introduction
5.2. Monoclonal antibody contracts dealmaking directory
Chapter 6 – Monoclonal antibody dealmaking by technology type
Deal directory
Deal directory – Monoclonal antibody deals by company A-Z
Deal directory – Monoclonal antibody deals by deal type
Deal directory – Monoclonal antibody deals by therapy area
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Monoclonal antibody deals since 2016
Figure 2: Active monoclonal antibody dealmaking activity
Figure 3: Monoclonal antibody deals by deal type since 2016
Figure 4: Monoclonal antibody deals by therapy area since 2016
Figure 5: Monoclonal antibody deals by industry sector since 2016
Figure 6: Monoclonal antibody deals with a headline value
Figure 7: Monoclonal antibody deals with an upfront value
Figure 8: Monoclonal antibody deals with a milestone value
Figure 9: Monoclonal antibody deals with a royalty rate value
Figure 10: Top monoclonal antibody deals by value since 2016
Figure 11: Most active monoclonal antibody dealmakers
Figure 12: Monoclonal antibody deals by technology type since 2016
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $7,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
